WallStreetZenWallStreetZen

NASDAQ: MOR
Morphosys Ag Stock

$17.58-0.09 (-0.51%)
Updated Feb 28, 2024
MOR Price
$17.58
Fair Value Price
N/A
Market Cap
$2.41B
52 Week Low
$3.65
52 Week High
$17.87
P/E
25.63x
P/B
71.45x
P/S
3.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$311.53M
Earnings
$96.91M
Gross Margin
82.2%
Operating Margin
80.35%
Profit Margin
30.1%
Debt to Equity
66.65
Operating Cash Flow
N/A
Beta
0.96
Next Earnings
Mar 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

MOR Overview

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MOR is good value based on its earnings relative to its share price (25.63x), compared to the US market average (35.52x)
P/E vs Market Valuation
MOR is poor value based on its earnings relative to its share price (25.63x), compared to the US Biotechnology industry average (13.96x)
P/E vs Industry Valuation
MOR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more MOR due diligence checks available for Premium users.

Be the first to know about important MOR news, forecast changes, insider trades & much more!

MOR News

Valuation

MOR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
25.63x
Industry
13.96x
Market
35.52x
MOR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MOR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

MOR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
71.45x
Industry
6.14x
MOR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MOR's financial health

Profit margin

Revenue
$58.4M
Net Income
-$81.3M
Profit Margin
-139.1%
MOR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$2.4B
Liabilities
$2.3B
Debt to equity
66.65
MOR's short-term assets ($917.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MOR's long-term liabilities ($1.99B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$138.4M
Investing
N/A
Financing
N/A

MOR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
MOR$2.41B-0.51%25.63x71.45x
GLPG$2.38B-1.80%N/A0.86x
CORT$2.45B-1.86%23.24x4.84x
VCEL$2.28B-0.42%-217.27x11.16x
ARDX$2.20B-2.17%-31.53x13.20x

Morphosys Ag Stock FAQ

What is Morphosys Ag's quote symbol?

(NASDAQ: MOR) Morphosys Ag trades on the NASDAQ under the ticker symbol MOR. Morphosys Ag stock quotes can also be displayed as NASDAQ: MOR.

If you're new to stock investing, here's how to buy Morphosys Ag stock.

What is the 52 week high and low for Morphosys Ag (NASDAQ: MOR)?

(NASDAQ: MOR) Morphosys Ag's 52-week high was $17.87, and its 52-week low was $3.65. It is currently -1.62% from its 52-week high and 381.64% from its 52-week low.

How much is Morphosys Ag stock worth today?

(NASDAQ: MOR) Morphosys Ag currently has 34,231,943 outstanding shares. With Morphosys Ag stock trading at $17.58 per share, the total value of Morphosys Ag stock (market capitalization) is $2.41B.

Morphosys Ag stock was originally listed at a price of $26.31 in Apr 19, 2018. If you had invested in Morphosys Ag stock at $26.31, your return over the last 5 years would have been -33.18%, for an annualized return of -7.75% (not including any dividends or dividend reinvestments).

How much is Morphosys Ag's stock price per share?

(NASDAQ: MOR) Morphosys Ag stock price per share is $17.58 today (as of Feb 28, 2024).

What is Morphosys Ag's Market Cap?

(NASDAQ: MOR) Morphosys Ag's market cap is $2.41B, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Morphosys Ag's market cap is calculated by multiplying MOR's current stock price of $17.58 by MOR's total outstanding shares of 34,231,943.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.